【摘要】 目的 系统回顾有关协议期内国家医保谈判药品(以下简称“国谈药”)可及性的文献，以总结我国国谈药可及性的改善情况。方法 检索中国知网、万方数据知识服务平台、维普网、中国生物医学文献系统、PubMed、Web of Science等数据库，收集有关国谈药可及性的公开发表文献，并对文献内容进行提取分析。结果 共纳入文献25篇，其中17篇关注谈判准入对国谈药可及性的影响，其余8篇则研究谈判准入后国谈药可及性的现状。针对可获得性，所有文献均发现国谈政策对药品使用量的提升具有显著正向效应，而40%(10/25)的文献发现国谈药的可获得性存在一定的地区或机构差异。针对可负担性，60%(15/25)的文献进行了研究，发现谈判准入后国谈药的价格急剧下降。然而，27%(4/15)的文献提到大多数抗肿瘤药物的自付费用仍较高。结论 国谈政策有效地提高了药品可及性，但仍需持续推动国谈药落地使用，并提升医保用药待遇。更多还原

【Abstract】 Objective To systematically review the literature on the accessibility of national medicare negotiated drugs and summarize its improvement. Methods CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science were searched to collect published literature about national medicare negotiated drugs accessibility, and analyze the content of the literature. Results 25 literatures were included, of which 17 focus on the impact of national medicare negotiated drugs accessibility, while the remaining 8 research the current status of national medicare negotiated drugs accessibility after the policy. Regarding availability, all of the literature found that the policy had a significant positive effect on the uptake of drugs, while 40%(10/25) found that there were some regional or institutional differences in the availability. Regarding affordability, only 60%(15/25) of the literature noted a sharp decrease in the price of national medicare negotiated drugs after the policy. However, 27%(4/15) mentioned that the out-of-pocket costs of most anticancer drugs were still high.Conclusion The National Price Negotiation policy has effectively improved drug accessibility, but it is still necessary to continuously promote the use of national medicare negotiated drugs and to improve the treatment of medicines in health insurance.更多还原